5.81  -0.02 (-0.34%)		02-28 16:00
Open: 5.83 High: 5.97 Volume: 64,126		Pre. Close: 5.83 Low: 5.79 Market Cap: 200(M)

Short term
Mid term
Targets	6-month :	7.52	1-year :	8.78
Resists	First :	6.44	Second :	7.52
Pivot price	5.89
Supports	First :	5.33	Second :	4.65
MAs	MA(5) :	6.02	MA(20) :	5.79
	MA(100) :	5.19	MA(250) :	5.22
MACD	MACD :	0.2	Signal :	0.2
%K %D	K(14,3) :	51.9	D(3) :	61.7
RSI	RSI(14): 55
52-week	High :	6.92	Low :	4

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ KMPH ] has closed above bottom band by 46.7%. Bollinger Bands are 0.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	6.03 - 6.07	6.07 - 6.11
Low:	5.6 - 5.65	5.65 - 5.7
Close:	5.78 - 5.86	5.86 - 5.93

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077 which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. and Commave Therapeutics SA. The company was incorporated in 2006 and is headquartered in Celebration, Florida.

Wed, 22 Feb 2023
KemPharm Announces Corporate Name Change to Zevra Therapeutics - Yahoo Finance

Fri, 29 Oct 2021
KemPharm Inc (KMPH) Down 3.68% in Premarket Trading - InvestorsObserver

Fri, 09 Apr 2021
KemPharm Amends Licensing Agreement With Gurnet Point Capital, Increases Milestone Payments To $590M - Yahoo Finance

Wed, 03 Mar 2021
KemPharm (KMPH) Soars on FDA Nod for ADHD Treatment, Azstarys - Yahoo Finance

Thu, 25 Feb 2021
EX-99.1 - SEC.gov

Wed, 23 Dec 2020
KemPharm Announces 1-for-16 Reverse Stock Split - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	35 (M)
Shares Float	31 (M)
Held by Insiders	10.2 (%)
Held by Institutions	17.6 (%)
Shares Short	1,450 (K)
Shares Short P.Month	1,630 (K)

EPS	-0.92
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.72
Profit Margin	0 %
Operating Margin	-172 %
Return on Assets (ttm)	-9 %
Return on Equity (ttm)	-31.3 %
Qtrly Rev. Growth	46.2 %
Gross Profit (p.s.)	0.77
Sales Per Share	0.31
EBITDA (p.s.)	-0.52
Qtrly Earnings Growth	0 %
Operating Cash Flow	-15 (M)
Levered Free Cash Flow	-11 (M)

PE Ratio	-6.44
PEG Ratio	0
Price to Book value	2.15
Price to Sales	18.85
Price to Cash Flow	-13.39

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	2020-12-27
Ex-Dividend Date	Invalid DateTime.